10-Q Filing

REGENXBIO Inc. CIK: 1590877 Q3 2015

Filing Information

Form Type	10-Q
Accession Number	`0001193125-15-367340`
Period End Date	20150930
Filing Date	20151105
Fiscal Year	2015
Fiscal Period	Q3
XBRL Instance	rgnx-20150930.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 71 Income Statement 91 Cash Flow Statement 62

Balance Sheet 71 line items

Line Item	Tag	Value	Unit	Period
Convertible preferred stock, par value	`TemporaryEquityParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Convertible preferred stock, shares authorized	`TemporaryEquitySharesAuthorized`	4.30M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$982.00K	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$205.32M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
Marketable securities	`MarketableSecuritiesCurrent`	$8.03M	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, par value	`PreferredStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	0.00	shares	Point-in-time
Trade receivables	`TradeReceivablesHeldForSaleAmount`	$609.00K	USD	Point-in-time
Preferred stock, shares authorized	`PreferredStockSharesAuthorized`	10.00M	shares	Point-in-time
Trade receivables	`TradeReceivablesHeldForSaleAmount`	$805.00K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Related party receivables	`DueFromRelatedPartiesCurrent`	$750.00K	USD	Point-in-time
Preferred stock, shares issued	`PreferredStockSharesIssued`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Preferred stock, shares outstanding	`PreferredStockSharesOutstanding`	0.00	shares	Point-in-time
Unbilled receivables	`UnbilledReceivablesCurrent`	$327.00K	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.40M	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$28.00K	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	100.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	9.50M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$127.00K	USD	Point-in-time
Total current assets	`AssetsCurrent`	$3.03M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$215.49M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	26.31M	shares	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	2.65M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	26.31M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	2.65M	shares	Point-in-time
Marketable securities	`MarketableSecuritiesNoncurrent`	$11.01M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$385.00K	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	-	USD	Point-in-time
Cost method investments	`CostMethodInvestments`	$303.00K	USD	Point-in-time
Cost method investments	`CostMethodInvestments`	$303.00K	USD	Point-in-time
Deferred issuance costs	`DeferredCosts`	$157.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$128.00K	USD	Point-in-time
Total assets	`Assets`	$227.31M	USD	Point-in-time
Total assets	`Assets`	$3.49M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$334.00K	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$3.10M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$1.73M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$1.11M	USD	Point-in-time
Due to related party under services agreement	`DueToRelatedPartiesCurrent`	$1.42M	USD	Point-in-time
Related party promissory notes	`NotesPayableRelatedPartiesClassifiedCurrent`	$2.40M	USD	Point-in-time
Other related party payables	`DueToOtherRelatedPartiesClassifiedCurrent`	$3.76M	USD	Point-in-time
Other related party payables	`DueToOtherRelatedPartiesClassifiedCurrent`	$349.00K	USD	Point-in-time
Advance payments	`CustomerAdvancesCurrent`	$153.00K	USD	Point-in-time
Advance payments	`CustomerAdvancesCurrent`	$127.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$9.19M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$5.31M	USD	Point-in-time
Deferred rent	`DeferredRentCreditNoncurrent`	$198.00K	USD	Point-in-time
Total liabilities	`Liabilities`	$5.51M	USD	Point-in-time
Total liabilities	`Liabilities`	$9.19M	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Convertible preferred stock, value	`RedeemableNoncontrollingInterestEquityPreferredCarryingAmount`	$12.59M	USD	Point-in-time
Preferred stock; $0.0001 par value; no shares authorized, issued and outstanding at December 31, 2014; 10,000 shares authorized, and no shares issued and outstanding at September 30, 2015	`PreferredStockValue`	-	USD	Point-in-time
Preferred stock; $0.0001 par value; no shares authorized, issued and outstanding at December 31, 2014; 10,000 shares authorized, and no shares issued and outstanding at September 30, 2015	`PreferredStockValue`	-	USD	Point-in-time
Common stock; $0.0001 par value; 9,500 and 100,000 shares authorized at December 31, 2014 and September 30, 2015, respectively; 2,645 and 26,306 shares issued and outstanding at December 31, 2014 and September 30, 2015, respectively	`CommonStockValue`	$3.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$268.27M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$10.52M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-26.00K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-46.44M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-28.81M	USD	Point-in-time
Total stockholders' equity (deficit)	`StockholdersEquity`	$-18.29M	USD	Point-in-time
Total stockholders' equity (deficit)	`StockholdersEquity`	$221.81M	USD	Point-in-time
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	`LiabilitiesAndStockholdersEquity`	$227.31M	USD	Point-in-time
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	`LiabilitiesAndStockholdersEquity`	$3.49M	USD	Point-in-time

Income Statement 91 line items

Line Item	Tag	Value	Unit	Period
License revenue	`LicensesRevenue`	$65.00K	USD	1 Quarter
License revenue	`LicensesRevenue`	$635.00K	USD	3 Qtrs
License revenue	`LicensesRevenue`	$3.71M	USD	3 Qtrs
License revenue from related party	`RevenueFromRelatedParties`	$150.00K	USD	1 Quarter
License revenue from related party	`RevenueFromRelatedParties`	$1.00M	USD	1 Quarter
License revenue from related party	`RevenueFromRelatedParties`	$2.00M	USD	3 Qtrs
License revenue from related party	`RevenueFromRelatedParties`	$150.00K	USD	3 Qtrs
Reagent sales	`OtherSalesRevenueNet`	$317.00K	USD	3 Qtrs
Reagent sales	`OtherSalesRevenueNet`	$23.00K	USD	1 Quarter
Reagent sales	`OtherSalesRevenueNet`	$200.00K	USD	3 Qtrs
Reagent sales	`OtherSalesRevenueNet`	$61.00K	USD	1 Quarter
Grant revenue	`RevenueFromGrants`	$14.00K	USD	1 Quarter
Grant revenue	`RevenueFromGrants`	$800.00K	USD	3 Qtrs
Grant revenue	`RevenueFromGrants`	$310.00K	USD	1 Quarter
Grant revenue	`RevenueFromGrants`	$305.00K	USD	3 Qtrs
Total revenues	`Revenues`	$3.14M	USD	3 Qtrs
Total revenues	`Revenues`	$483.00K	USD	1 Quarter
Total revenues	`Revenues`	$1.14M	USD	1 Quarter
Total revenues	`Revenues`	$4.97M	USD	3 Qtrs
Licensing costs to related parties	`RelatedPartyCosts`	$213.00K	USD	1 Quarter
Licensing costs to related parties	`RelatedPartyCosts`	$527.00K	USD	3 Qtrs
Licensing costs to related parties	`RelatedPartyCosts`	$741.00K	USD	3 Qtrs
Costs of reagent sales (including amounts to related parties)	`CostOfGoodsSold`	$12.00K	USD	1 Quarter
Costs of reagent sales (including amounts to related parties)	`CostOfGoodsSold`	$44.00K	USD	1 Quarter
Costs of reagent sales (including amounts to related parties)	`CostOfGoodsSold`	$115.00K	USD	3 Qtrs
Costs of reagent sales (including amounts to related parties)	`CostOfGoodsSold`	$94.00K	USD	3 Qtrs
Research and development (including amounts to related parties)	`ResearchAndDevelopmentExpense`	$12.47M	USD	3 Qtrs
Research and development (including amounts to related parties)	`ResearchAndDevelopmentExpense`	$5.66M	USD	1 Quarter
Research and development (including amounts to related parties)	`ResearchAndDevelopmentExpense`	$1.08M	USD	1 Quarter
Research and development (including amounts to related parties)	`ResearchAndDevelopmentExpense`	$2.87M	USD	3 Qtrs
General and administrative (including amounts to related parties)	`GeneralAndAdministrativeExpense`	$2.73M	USD	3 Qtrs
General and administrative (including amounts to related parties)	`GeneralAndAdministrativeExpense`	$1.07M	USD	1 Quarter
General and administrative (including amounts to related parties)	`GeneralAndAdministrativeExpense`	$2.57M	USD	1 Quarter
General and administrative (including amounts to related parties)	`GeneralAndAdministrativeExpense`	$7.67M	USD	3 Qtrs
Foreign currency transaction losses (gains)	`ForeignCurrencyTransactionGainLossBeforeTax`	$-4.00K	USD	1 Quarter
Foreign currency transaction losses (gains)	`ForeignCurrencyTransactionGainLossBeforeTax`	$-12.00K	USD	3 Qtrs
Foreign currency transaction losses (gains)	`ForeignCurrencyTransactionGainLossBeforeTax`	$-41.00K	USD	3 Qtrs
Foreign currency transaction losses (gains)	`ForeignCurrencyTransactionGainLossBeforeTax`	$-25.00K	USD	1 Quarter
Other operating income	`OtherOperatingIncome`	$32.00K	USD	3 Qtrs
Other operating income	`OtherOperatingIncome`	$8.00K	USD	1 Quarter
Other operating income	`OtherOperatingIncome`	$5.00K	USD	1 Quarter
Other operating income	`OtherOperatingIncome`	$26.00K	USD	3 Qtrs
Total operating expenses	`CostsAndExpenses`	$6.44M	USD	3 Qtrs
Total operating expenses	`CostsAndExpenses`	$20.78M	USD	3 Qtrs
Total operating expenses	`CostsAndExpenses`	$2.18M	USD	1 Quarter
Total operating expenses	`CostsAndExpenses`	$8.49M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-1.70M	USD	1 Quarter
Loss from operations	`OperatingIncomeLoss`	$-1.47M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-17.64M	USD	3 Qtrs
Loss from operations	`OperatingIncomeLoss`	$-7.35M	USD	1 Quarter
Investment income	`InvestmentIncomeNet`	$15.00K	USD	1 Quarter
Investment income	`InvestmentIncomeNet`	$23.00K	USD	3 Qtrs
Interest expense	`InterestExpense`	$92.00K	USD	1 Quarter
Interest expense	`InterestExpense`	$202.00K	USD	3 Qtrs
Interest expense	`InterestExpense`	$20.00K	USD	3 Qtrs
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$15.00K	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-92.00K	USD	1 Quarter
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$3.00K	USD	3 Qtrs
Total other income (expense)	`OtherNonoperatingIncomeExpense`	$-202.00K	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-7.33M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.67M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.79M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.64M	USD	3 Qtrs
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-26.00K	USD	3 Qtrs
Unrealized loss on available-for-sale securities	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-26.00K	USD	1 Quarter
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-26.00K	USD	3 Qtrs
Total other comprehensive loss	`OtherComprehensiveIncomeLossNetOfTax`	$-26.00K	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-7.36M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-17.66M	USD	3 Qtrs
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-1.79M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTax`	$-1.67M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-7.33M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.67M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.79M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.64M	USD	3 Qtrs
Accretion and dividends on convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	$1.75M	USD	3 Qtrs
Accretion and dividends on convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	$592.00K	USD	3 Qtrs
Accretion and dividends on convertible preferred stock	`PreferredStockDividendsAndOtherAdjustments`	$126.00K	USD	1 Quarter
Net gain on extinguishment of convertible preferred stock	`GainLossOnExtinguishmentOfConvertiblePreferredStock`	$759.00K	USD	3 Qtrs
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-1.92M	USD	1 Quarter
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-18.62M	USD	3 Qtrs
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-2.26M	USD	3 Qtrs
Net loss applicable to common stockholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-7.33M	USD	1 Quarter
Basic and diluted net loss per common share	`EarningsPerShareBasicAndDiluted`	$-0.73	USD	1 Quarter
Basic and diluted net loss per common share	`EarningsPerShareBasicAndDiluted`	$-5.48	USD	3 Qtrs
Basic and diluted net loss per common share	`EarningsPerShareBasicAndDiluted`	$-1.52	USD	1 Quarter
Basic and diluted net loss per common share	`EarningsPerShareBasicAndDiluted`	$-0.85	USD	3 Qtrs
Weighted-average basic and diluted common shares	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	3.40M	shares	3 Qtrs
Weighted-average basic and diluted common shares	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	4.81M	shares	1 Quarter
Weighted-average basic and diluted common shares	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	2.64M	shares	1 Quarter
Weighted-average basic and diluted common shares	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	2.64M	shares	3 Qtrs

Cash Flow Statement 62 line items

Line Item	Tag	Value	Unit	Period
Net loss	`NetIncomeLoss`	$-7.33M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-1.67M	USD	3 Qtrs
Net loss	`NetIncomeLoss`	$-1.79M	USD	1 Quarter
Net loss	`NetIncomeLoss`	$-17.64M	USD	3 Qtrs
Unrealized foreign currency transaction gains	`ForeignCurrencyTransactionGainLossUnrealized`	$25.00K	USD	3 Qtrs
Unrealized foreign currency transaction gains	`ForeignCurrencyTransactionGainLossUnrealized`	$4.00K	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$2.06M	USD	3 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$220.00K	USD	3 Qtrs
Imputed interest on related party promissory notes	`ImputedInterestOnRelatedPartyDebt`	$45.00K	USD	3 Qtrs
Imputed interest on related party promissory notes	`ImputedInterestOnRelatedPartyDebt`	$13.00K	USD	3 Qtrs
Other non-cash adjustments	`OtherNoncashExpense`	$1.00K	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$43.00K	USD	3 Qtrs
Amortization of premiums on marketable debt securities	`AccretionAmortizationOfDiscountsAndPremiumsInvestments`	$-1.00K	USD	3 Qtrs
Trade receivables	`IncreaseDecreaseInAccountsReceivable`	$1.10M	USD	3 Qtrs
Trade receivables	`IncreaseDecreaseInAccountsReceivable`	$-200.00K	USD	3 Qtrs
Related party receivables	`IncreaseDecreaseInDueFromRelatedPartiesCurrent`	$-774.00K	USD	3 Qtrs
Related party receivables	`IncreaseDecreaseInDueFromRelatedPartiesCurrent`	$-750.00K	USD	3 Qtrs
Unbilled receivables	`IncreaseDecreaseInUnbilledReceivables`	$-30.00K	USD	3 Qtrs
Unbilled receivables	`IncreaseDecreaseInUnbilledReceivables`	$-327.00K	USD	3 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$1.37M	USD	3 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$131.00K	USD	3 Qtrs
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$127.00K	USD	3 Qtrs
Other assets	`IncreaseDecreaseInOtherOperatingAssets`	$128.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$317.00K	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$440.00K	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$295.00K	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$758.00K	USD	3 Qtrs
Due to related party under services agreement	`IncreaseDecreaseInAccountsPayableRelatedParties`	$-255.00K	USD	3 Qtrs
Due to related party under services agreement	`IncreaseDecreaseInAccountsPayableRelatedParties`	$-34.00K	USD	3 Qtrs
Other related party payables	`IncreaseDecreaseInDueToOtherRelatedPartiesCurrent`	$-3.41M	USD	3 Qtrs
Other related party payables	`IncreaseDecreaseInDueToOtherRelatedPartiesCurrent`	$-1.33M	USD	3 Qtrs
Advance payments	`IncreaseDecreaseInCustomerAdvances`	$-26.00K	USD	3 Qtrs
Advance payments	`IncreaseDecreaseInCustomerAdvances`	$168.00K	USD	3 Qtrs
Deferred rent	`IncreaseDecreaseInDeferredRentPayable`	$198.00K	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-2.54M	USD	3 Qtrs
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivitiesContinuingOperations`	$-18.07M	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$19.07M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$394.00K	USD	3 Qtrs
Net cash used in investing activities	`NetCashProvidedByUsedInInvestingActivitiesContinuingOperations`	$-19.46M	USD	3 Qtrs
Proceeds from related party promissory notes	`ProceedsFromRelatedPartyDebt`	$2.40M	USD	3 Qtrs
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$100.00K	USD	3 Qtrs
Proceeds from initial public offering of common stock, net of underwriting discounts and commissions	`ProceedsFromIssuanceInitialPublicOffering`	$148.23M	USD	3 Qtrs
Payments of initial public offering costs	`PaymentsOfStockIssuanceCosts`	$618.00K	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$2.40M	USD	3 Qtrs
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivitiesContinuingOperations`	$241.73M	USD	3 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-137.00K	USD	3 Qtrs
Net increase (decrease) in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$204.20M	USD	3 Qtrs
Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$982.00K	USD	Point-in-time
Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$205.32M	USD	Point-in-time
Beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
End of period	`CashAndCashEquivalentsAtCarryingValue`	$982.00K	USD	Point-in-time
End of period	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
End of period	`CashAndCashEquivalentsAtCarryingValue`	$205.32M	USD	Point-in-time
End of period	`CashAndCashEquivalentsAtCarryingValue`	$1.12M	USD	Point-in-time
Cash paid for interest	`InterestPaid`	$7.00K	USD	3 Qtrs
Cash paid for interest	`InterestPaid`	$164.00K	USD	3 Qtrs
Conversion of accrued service fees into Series C convertible preferred stock	`ConversionOfRelatedPartyAccruedServiceFeesToConvertiblePreferredStock`	$2.40M	USD	3 Qtrs
Conversion of related party promissory notes into Series C convertible preferred stock	`DebtConversionConvertedInstrumentAmount1`	$1.39M	USD	3 Qtrs
Conversion of convertible preferred stock into common stock upon initial public offering	`ConversionOfStockAmountConverted1`	$111.39M	USD	3 Qtrs
Purchases of property and equipment in accounts payable	`CapitalExpendituresIncurredButNotYetPaid`	$34.00K	USD	3 Qtrs
Issuance costs for initial public offering in accounts payable and accrued expenses	`IssuanceCostsForInitialPublicOfferingInAccountsPayableAndAccruedExpenses`	$2.43M	USD	3 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.